- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04608136
Egg Yolk and Underlying Metabolisms on Modifying HDL Levels in Individuals With Metabolic Syndrome
7. april 2022 oppdatert av: Mahidol University
Egg Yolk and Underlying Metabolisms on Modifying HDL Levels and Associated Genetics in Individuals With Metabolic Syndrome
This research compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This research study examines the effects of changes in weight, metabolism of glucose and cholesterol in the blood through diet and behavior modification.
The main objective of this study was to compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people.
In addition, HDL quantity and size as well as HDL function was compared between the group who ate the whole egg and the group who did not eat the yolk.
Studietype
Intervensjonell
Registrering (Faktiske)
76
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Bangkok
-
Bangkok Noi, Bangkok, Thailand, 10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 60 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- weight stable > 3 months (changing < 5%)
- three or more of the following five criteria are met 2.1 waist circumference ≥ 90 cm (men) or ≥ 80 cm (women) 2.2 fasting blood sugar ≥ 100 mg/dl 2.3 fasting triglyceride (TG) level ≥ 150 mg/dl 2.4 fasting high-density lipoprotein (HDL) cholesterol level ≤ 40 mg/dl (men) or ≤ 50 mg/dl (women) 2.5 blood pressure over 130/85 mmHg
- can consume food that provided in project
- healthy
Exclusion Criteria:
- consume drugs i.e. weight loss drugs, herbal pills, asthma drugs, steroid drugs, thyroid drugs, insulin injections, SGLT1 inhibitors drugs, SGLT2 inhibitors drugs, sulfonylurea drugs, blood lipid-lowering drugs
- people who exercise vigorously (> 150 minutes per week)
- people who are or have weight loss by consuming less than 30% of carbohydrates, or are losing weight by other methods or who have eaten a specific diet as prescribed by a doctor within the past 6 months
- people who drink alcohol more than once a week
- people who had a LDL level within 6 months > 190 mg/dl
- fasting blood glucose levels > 250 mg/dl and using diabetes drugs other than metformin
- people with heart disease, type 1 diabetes, renal impairment > level 3A
- history of cancer, lung disease, gastrointestinal disease
- people who smoke, people with eating disorder, people who have received psychiatric drugs
- become a volunteer in a research project that is conducting a study related to food consumption
- people who are unable to keep up with the treatment or are expected to be absent in this area for the next 4 months
- pregnancy or breastfeeding
- egg allergy
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Yolk ketogenic diet
consume carbohydrate < 10% and 3 whole eggs supplement per day in 12 weeks
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
|
Eksperimentell: White ketogenic diet
consume carbohydrate < 10% and 6 white eggs supplement per day in 12 weeks
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
|
Aktiv komparator: Control group
decrease consumption of diet from typical (decreased energy 20%) but consume carbohydrate in normal level
|
Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in weight following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
weight (kg) analysis
|
Baseline and after 12 weeks
|
|
Changes in body mass index following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
body mass index (kg/m^2) analysis
|
Baseline and after 12 weeks
|
|
Changes in waist circumference following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
waist circumference (cm) analysis
|
Baseline and after 12 weeks
|
|
Changes in lipid profiles concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
Triglycerides (mg/dl), Cholesterol (mg/dl), HDL-cholesterol (mg/dl) and LDL-cholesterol (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in blood glucose and insulin concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
HbA1C (%), glucose (mg/dl) and insulin (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in betahydroxybutirate concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
betahydroxybutirate (mmol/L) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in electrolytes concentration following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
Na+ (mg/dl), K+ (mg/dl), Cl- (mg/dl) and HCO3- (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in physical activity
Tidsramme: Baseline and after 12 weeks
|
physical activity (MET-minutes/week) collect data by using questionnaires
|
Baseline and after 12 weeks
|
|
Change from baseline Glycemia at 180 minutes
Tidsramme: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
glucose (mg/dl)
|
Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
|
Change from baseline Insulin at 180 minutes
Tidsramme: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
insulin (μU/ml)
|
Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in blood pressure
Tidsramme: Baseline and after 12 weeks
|
systolic and diastolic blood pressure (mmHg)
|
Baseline and after 12 weeks
|
|
Changes in fasting leptin levels
Tidsramme: Baseline and after 12 weeks
|
leptin (mg/dl) concentration analysis
|
Baseline and after 12 weeks
|
|
Changes in energy intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
energy (kcal)
|
Baseline and after 12 weeks
|
|
Changes in carbohydrate following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
carbohydrate (g)
|
Baseline and after 12 weeks
|
|
Changes in protein intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
protein (g)
|
Baseline and after 12 weeks
|
|
Changes in fat intake following dietary intervention
Tidsramme: Baseline and after 12 weeks
|
fat (g)
|
Baseline and after 12 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
21. september 2020
Primær fullføring (Faktiske)
31. mai 2021
Studiet fullført (Faktiske)
31. desember 2021
Datoer for studieregistrering
Først innsendt
21. september 2020
Først innsendt som oppfylte QC-kriteriene
28. oktober 2020
Først lagt ut (Faktiske)
29. oktober 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
8. april 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
7. april 2022
Sist bekreftet
1. april 2022
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MU-CIRB 2019/255.0310
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Metabolsk syndrom
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbeidspartnereHar ikke rekruttert ennåLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitt | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpania
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
-
Tangram Therapeutics PlcRekrutteringFriske deltakere | MASH - Metabolic Dysfunction-Associated SteatohepatittStorbritannia
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittKina
-
Southern California Institute for Research and...Har ikke rekruttert ennåMASH - Metabolic Dysfunction-Associated Steatohepatitt
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittPakistan
-
University of Campania Luigi VanvitelliFullførtMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
-
University of Campania Luigi VanvitelliFullførtKardiovaskulære hendelser | MASLD | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia
Kliniske studier på Diet intervention
-
Ji JingFullførtSvangerskapsdiabetes mellitus (GDM)Kina
-
Rush University Medical CenterUniversity of Chicago; National Institute on Aging (NIA); Advocate Hospital...Aktiv, ikke rekrutterendeSlag | Demens | Alzheimers sykdom | Demens, vaskulær | Kognitiv nedgangForente stater
-
Ohio State University Comprehensive Cancer CenterRekruttering
-
University of Texas at AustinNational Cattlemen's Beef AssociationFullførtSpiseatferd | Amming, eksklusivt | Glykemisk responsForente stater
-
Kaiser PermanenteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbeidspartnereFullførtPsykotiske lidelser | Diabetes mellitus, type 2 | VekttapForente stater
-
Pronacera Therapeutics SLCentre for the Development of Industrial Technology, SpainAktiv, ikke rekrutterende
-
Vastra Gotaland RegionGöteborg UniversityPåmelding etter invitasjon
-
Laval UniversityUniversité de Montréal; Centre de Recheche du Centre Hospitalier Université...FullførtKardiovaskulære sykdommer | Familiær hyperkolesterolemi | Kolesterol, forhøyet | Ernæring, sunn | Kolesterol; Metabolsk forstyrrelseCanada
-
Terry L. WahlsNational Multiple Sclerosis SocietyFullførtMultippel sklerose | Multippel sklerose, tilbakefallende-remitterendeForente stater
-
USDA Grand Forks Human Nutrition Research CenterEgg Nutrition CenterAvsluttet